Immunicum AB (publ) announces that it has received clearance from the Medical Products Agency and the Ethics Committee to start its fourth clinical study with the cancer immune primer INTUVAX. The study will be conducted on 12 patients with gastrointestinal stromal tumor (GIST) at the Karolinska University Hospital in Stockholm.
Read the press release here: Press release 151216 – Approval to start GIST phase I-II-study
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805